GREENWOOD VILLAGE, Colo.
July 18, 2012
/PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ & Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced the closing of a
underwritten public offering of 5,488,960 shares of common stock, including 692,310 shares of common stock which were sold by Ampio and certain of its stockholders pursuant to the exercise of the underwriters' over-allotment option, at a price of
per share. Ampio received gross proceeds of
from the offering and the selling stockholders received gross proceeds of
from the offering. Ampio will not receive any of the proceeds from the sale of shares by the selling stockholders.
Aegis Capital Corp. and Fordham Financial Management, Inc. acted as joint book-running managers for the offering.
The offering was made pursuant to a shelf registration statement that Ampio filed with the Securities and Exchange Commission ("SEC") and is effective. The prospectus supplements relating to the offering were filed with the SEC and are available on the website of the SEC at
. Copies of the prospectus supplements relating to the offering may also be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor,
New York, NY
, 10019, telephone: 212-813-1010 or email:
or Fordham Financial Management, Inc., 17 Battery Place, South, Suite 643,
New York, New York
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.